Meir Yoeli - Nextage Therapeutics Chief Executive Officer
MCTC Stock | ILA 70.00 6.10 8.02% |
CEO
Mr. Meir Yoeli was appointed Chief Executive Officer at Micromedic Technologies Ltd effective January 20, 2019. His work experience includes the following roles Vice PresidentOperations at Real Imaging Ltd, Vice PresidentBusiness Development at Real Imaging Ltd and Chief Executive Officer at Real Imaging Ltd . He holds a LLB degree from The Interdisciplinary Center Herzliya and a BS degree in Electrical and Electronics Engineering and a MBA degree, both from Tel Aviv University. since 2019.
Age | 71 |
Tenure | 5 years |
Professional Marks | MBA |
Phone | 972 73 2753450 |
Web | http://www.m-medic.com |
Nextage Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3684) % which means that it has lost $0.3684 on every $100 spent on assets. This is way below average. Nextage Therapeutics' management efficiency ratios could be used to measure how well Nextage Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Found 3 records | CEO Age | ||
David Mizrahi | Bezeq Israeli Telecommunication | 53 | |
Ran Guron | Bezeq Israeli Telecommunication | 55 | |
Amir London | Kamada | 54 |
Management Performance
Return On Asset | -0.37 |
Nextage Therapeutics Leadership Team
Elected by the shareholders, the Nextage Therapeutics' board of directors comprises two types of representatives: Nextage Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nextage. The board's role is to monitor Nextage Therapeutics' management team and ensure that shareholders' interests are well served. Nextage Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nextage Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Meir Yoeli, Chief Executive Officer | ||
Itai BarNatan, Chief Officer | ||
Yifftach Biel, Deputy Vice President - Finance | ||
Yael Glickman, VP Devel | ||
Doron Debbie, Independent Director |
Nextage Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nextage Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Asset | -0.37 | |||
Profit Margin | (2.30) % | |||
Operating Margin | (9.71) % | |||
Shares Outstanding | 2.27 M | |||
Shares Owned By Insiders | 22.39 % | |||
Shares Owned By Institutions | 0.02 % | |||
Price To Earning | (91.98) X | |||
Price To Book | 4.68 X | |||
Price To Sales | 26.11 X | |||
Revenue | 297 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nextage Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Nextage Stock analysis
When running Nextage Therapeutics' price analysis, check to measure Nextage Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nextage Therapeutics is operating at the current time. Most of Nextage Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nextage Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nextage Therapeutics' price. Additionally, you may evaluate how the addition of Nextage Therapeutics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |